Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019

Summary

According to the recently published report Survival Motor Neuron Protein - Pipeline Review, H1 2019; Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 18 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs). They play an important role in the splicing of cellular pre-mRNAs. They ensure the correct splicing of U12 intron-containing genes that is important for normal motor and proprioceptive neurons development. They are required for resolving RNA-DNA hybrids created by RNA polymerase II. They play a role in the metabolism of small nucleolar ribonucleoprotein.

The report Survival Motor Neuron Protein - Pipeline Review, H1 2019 outlays comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 7 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Spinal Muscular Atrophy (SMA) and Cystic Fibrosis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
- The report reviews Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

TABLE OF CONTENTS

Introduction
Global Markets Direct Report Coverage
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Overview
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Companies Involved in Therapeutics Development
AveXis Inc
Biogen Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Ionis Pharmaceuticals Inc
Novartis AG
Sarepta Therapeutics Inc
Spotlight Innovation Inc
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Drug Profiles
ALB-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
branaplam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISENAC-2.5Rx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LDN-5178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onasemnogene abeparvovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMO-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
risdiplam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 2 to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STL-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Dormant Products
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Discontinued Products
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Product Development Milestones
Featured News & Press Releases
Apr 03, 2019: ICER Issues Final Report on Zolgensma, provides Policy recommendations related to Pricing and Coverage of treatments for Spinal Muscular Atrophy
Apr 01, 2019: AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Mar 27, 2019: Chugai receives Orphan Drug Designation for Risdiplam in Spinal Muscular Atrophy
Feb 18, 2019: Gene Therapy Firm AveXis to expand in Durham County adding 200 jobs and $60 Million in investment
Feb 01, 2019: First phase 3 gene therapy trial in spinal muscular atrophy at The John Walton Muscular Dystrophy Centre
Jan 08, 2019: Genentech, Roche and PTC Therapeutics provide update on Regulatory Filing for Risdiplam
Dec 19, 2018: Roche gets PRIME designation for SMA drug in Europe
Dec 03, 2018: Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
Nov 05, 2018: Novartis provides update on AVXS101
Oct 03, 2018: Roche announces new data for Risdiplam in spinal muscular atrophy(SMA) at the World Muscle Society Congress
Oct 03, 2018: Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
Jul 24, 2018: Spotlight Innovation spinal muscular atrophy research collaborator professor Kevin Hodgetts receives $300,000 grant from Cure SMA
Jun 16, 2018: Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference
Jun 14, 2018: Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas
May 08, 2018: AveXis Issues Community Statement on the SPR1NT Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AveXis Inc, H1 2019
Pipeline by Biogen Inc, H1 2019
Pipeline by Exicure Inc, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Ionis Pharmaceuticals Inc, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Sarepta Therapeutics Inc, H1 2019
Pipeline by Spotlight Innovation Inc, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019

List Of Figures

Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019

Survival Motor Neuron Protein - Pipeline Review, H1 2020

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2017

Motor Neuron Diseases (Central Nervous System) - Drugs in Development, 2021

Survival Motor Neuron Protein - Pipeline Review, H1 2020

FAQs